Investor Relations

Frank Karbe has over 25 years of financial and life-sciences expertise and helped build companies that successfully developed and commercialized multiple products. He also has a long standing passion for the intersection of medical science and digital technology and how it may be applied to improve human health. Prior to Better Therapeutics, he was President and Chief Financial Officer of Myovant Sciences where he led the company's efforts to raise approximately $2 billion in capital and its evolution from a private start-up organization to a publicly listed commercial stage company with two marketed products. He also served as Executive Vice President and Chief Financial Officer at Exelixis, Inc. for over a decade, as the company evolved from a discovery to a commercial organization. Earlier in his career, Mr. Karbe worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.

Dr. Mark Berman serves as Better’s Chief Medical Officer. Previously, he practiced as an internal and lifestyle medicine physician at One Medical. Dr. Berman received his M.D. from Yale. He completed residency at Harvard’s Brigham and Women’s Hospital and a clinical research fellowship at University of California, San Francisco. He has also served as a director of the American College of Lifestyle Medicine.

Kristin Wynholds is Better’s Chief Product Officer. Most recently, she was Principal Product Designer at Carbon Five, a digital product development consultancy. Ms. Wynholds has led or been involved with more than 30 digital product launches for companies including Stanford Health and Grand Rounds. Ms. Wynholds has a B.A. degree in psychology from UC Santa Barbara.

Jessica serves as Better's Chief Commercial Officer. She has a 20+ year track record in healthcare and extensive product launch leadership. In her most recent role as Chief Commercial Officer of DELFI Diagnostics, Jessica created and drove a nontraditional go-to-market strategy to gain early adoption of a revolutionary blood screening test for cancer, well ahead of guideline inclusion and broad reimbursement. She led the Women's Health Division of Myovant Sciences as General Manager and Vice President of Sales & Marketing, where she played a key role in the formation of the partnership with Pfizer. Prior to Myovant, Jessica was Vice President of Marketing for Veracyte, launching multiple genomic diagnostic products in oncology and pulmonology and helping to grow the commercial organization's headcount from 50 to 200. Jessica spent 10+ years in commercial leadership roles of increasing responsibilities at Genentech, most notably leading the marketing of Genentech's blockbuster oncology product, Avastin, to the height of its commercial success in gastrointestinal and gynecological cancers as well as glioblastoma. Jessica holds an MBA from the Wharton School of Business and Undergraduate degrees in Finance and International Relations from University of Pennsylvania.

Andres Camacho leads all of our engineering efforts and has been writing code and leading software teams for more than 20 years. Prior to working at Better, Andres was VP of Engineering at Manilla and Vinfolio. Andres earned his B.S. in finance at University of Texas at Austin and studied computer science at San Francisco State University.

Angela Willis serves as Senior Vice President of Market Access and has more than 20 years of experience in the biopharmaceutical industry. Most recently, Ms. Willis spent 18 years at Amgen in multiple therapeutic areas, working primarily in Market Access and Sales leadership roles. Prior to Amgen, she worked at both Novartis and Serono in Sales and Sales leadership roles. Over the past 4.5 years, Ms. Willis has led the market access function at several smaller, startup companies, including Alder Biopharmaceuticals, Arrowhead, and Revance, to prepare the organizations for commercialization of their first asset. She has a B.S. in Biology from the University of Pittsburgh.